Draig Therapeutics
Draig Therapeutics develops neuropsychiatric medicines.
$65MSeries B
Role not disclosedCP
Canaan Partners
Activity from announced rounds
Activity in this selectionOct 23, 2026 · Europe · Jan 1, 2026
Canaan Partners is an investment firm whose company directory identifies Draig Therapeutics and Solstice Oncology.
Recorded funding activity
Draig develops neuropsychiatric medicines, while Solstice advances an engineered CTLA-4 antibody for cancer treatment. The recorded history also includes Actualyze AI’s enterprise gateway for model access, request security, budgets and routing. Named regional funds retain separate identities.
Sources
- Rounds participated in
- 2
- Confirmed lead rounds
- 1 1 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $73.5M 2 disclosed · full round size, not this investor’s share